In contrast, the role of TILs in ER+HER2- breast cancers remains elusive [52] and may identify tumors exhibiting unfavorable clinicopathological factors, such as high tumor grade, more advanced stage, and younger age, resulting in poorer clinical outcomes. Here, ERBB2 is linked to breast carcinoma.